Entering text into the input field will update the search result below

Gilead's simtuzumab an Orphan Drug for rare liver disease

Jan. 07, 2015 1:39 PM ETGilead Sciences, Inc. (GILD) StockGILDBy: Douglas W. House, SA News Editor31 Comments
  • The FDA grants Orphan Drug status to Gilead Sciences' (GILD +1.2%) simtuzumab for the treatment of primary sclerosing cholengitis, a disease of the bile ducts that causes inflammation and can lead to cirrhosis and liver failure.
  • Among the benefits of the Orphan Drug tag is a seven-year period of market exclusivity if approved.
  • Gilead is also developing simtuzumab for liver fibrosis and nonalcoholic steatohepatitis (NASH).

Recommended For You

About GILD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GILD--
Gilead Sciences, Inc.